The European Society for Radiotherapy and Oncology (ESTRO) is set to release new clinical guidelines in 2026 to standardize focal boosting in prostate cancer radiotherapy. By providing a framework for delivering higher radiation doses to dominant intraprostatic lesions, these recommendations aim to improve local control rates while minimizing toxicity to surrounding healthy tissues.
Why Focal Boosting Is Evolving in Prostate Cancer Care
Focal boosting—the practice of intensifying radiation to the most aggressive part of a tumor—has become a significant area of interest in oncological research. According to the ESTRO Prostate Cancer Guidelines, current clinical practice often varies significantly between institutions regarding dose volume and delivery techniques.
The upcoming 2026 guidance addresses the limitations of whole-gland irradiation. While traditional radiotherapy treats the entire prostate, it may under-dose the specific regions harboring the highest-grade cancer cells. By utilizing multiparametric MRI and PSMA-PET imaging, clinicians can now pinpoint these "dominant lesions." The new ESTRO standards will provide evidence-based parameters on how to safely escalate doses to these specific areas without increasing the risk of rectal or urinary side effects.
How the 2026 Guidelines Will Impact Treatment Planning
The shift toward focal boosting relies heavily on high-precision imaging. As noted in recent updates from the European Association of Urology (EAU), the integration of diagnostic imaging into the radiotherapy planning process is essential for accurate target delineation.
The ESTRO 2026 framework is expected to clarify several technical hurdles:
- Target Definition: Standardizing how clinicians contour the dominant intraprostatic lesion (DIL).
- Dose Constraints: Defining clear safety limits for the bladder, rectum, and penile bulb when high-dose radiation is applied to a focal spot.
- Imaging Modalities: Establishing which imaging sequences (e.g., T2-weighted MRI, diffusion-weighted imaging, or PSMA-PET) are mandatory for defining the boost volume.
Comparison: Whole-Gland vs. Focal Boosting
Clinical strategies have shifted as technology has improved. The following table highlights the primary differences in these approaches based on contemporary radiotherapy practices.
| Feature | Whole-Gland Radiotherapy | Focal Boosting |
|---|---|---|
| Dose Distribution | Uniform across the prostate | Higher dose to the tumor lesion |
| Toxicity Risk | Standard risk to surrounding organs | Potential for lower overall toxicity |
| Imaging Requirement | Standard planning CT/MRI | Advanced MRI/PET fusion required |
| Primary Goal | Eradication of entire gland | Targeted control of aggressive foci |
What Happens Next for Prostate Cancer Patients
Patients currently undergoing radiotherapy may discuss the potential for focal boosting with their radiation oncologists, though practice remains subject to individual institutional protocols until the 2026 ESTRO guidelines are officially published.
The move toward these standardized guidelines reflects a broader trend in precision oncology: treating the tumor based on its specific biological and anatomical characteristics rather than treating the organ as a uniform structure. As clinical evidence continues to mature, these guidelines will serve as the benchmark for radiation oncologists across Europe and beyond, ensuring that patients receive consistent, high-quality care that prioritizes both cancer control and quality of life.